Rosen ED, Kaestner KH, Natarajan R, et al. Epigenetics and Epigenomics: Implications for Diabetes and Obesity. Diabetes. 2018;67(10):1923-1931. doi:10.2337/db18-0537.

Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976. doi:10.1016/j.cell.2017.02.004.

O'Sullivan JF, Morningstar JE, Yang Q, et al. Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. J Clin Invest. 2017;127(12):4394-4402. doi:10.1172/JCI95995.

Florez JC. Genetics and biobanks converge to resolve a vexing knowledge gap in diabetes. Lancet Diabetes Endocrinol. 2018;6(2):87-89. doi:10.1016/S2213-8587(17)30399-6.

Merino J, Florez JC. Precision medicine in diabetes: an opportunity for clinical translation. Ann N Y Acad Sci. 2018;1411(1):140-152. doi:10.1111/nyas.13588.

Habeb AM, Flanagan SE, Zulali MA, et al. Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome. Diabetologia. 2018;61(5):1027-1036. doi:10.1007/s00125-018-4554-x.

Grimsby JL, Porneala BC, Vassy JL, et al. Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III). BMC Med Genet. 2012;13:30. doi:10.1186/1471-2350-13-30.

Wagner BK. Grand challenge commentary: Chemical transdifferentiation and regenerative medicine. Nat Chem Biol. 2010;6(12):877-9. doi:10.1038/nchembio.472.

Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-53. doi:10.1038/nm.2307.

Efeyan A, Zoncu R, Sabatini DM. Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med. 2012;18(9):524-33. doi:10.1016/j.molmed.2012.05.007.